Life-threatening diseases require precision at the cellular level. Qtas brings quantum sensing to single-cell analysis, delivering an entirely new understanding of disease. Our platform is the world's smallest MRI, designed specifically for pharma, clinical, and translational research workflows. It recovers rare cells one by one directly in native blood or cerebrospinal fluid to identify disease long before it shows up on a scan. Starting with oncology, our ambition is to pave the way to a new generation of precision medicine across prenatal health, cardiovascular disease, and drug development. By revealing richer biological insights hidden by bulk and population-average measurements, Qtas leads to faster diagnostics, more effective treatment monitoring, and better outcomes for each patient. Behind every cell is a patient. Behind every patient is a life worth fighting for. Let's make personalised medicine a standard. Not for some. For all.
| Website | http://www.qtas.com |
| Employees | 6 (6 on RocketReach) |
| Founded | 2025 |
| Address | Lichtenbergstraße, Garching, Bavaria 85748, DE |
| Industry | Research |
Looking for a particular QTAS employee's phone or email?
Robin Allert is the CEO and Co-Founder of QTAS.
6 people are employed at QTAS.
QTAS is based in Garching, Bavaria.